Polyrizon Stock (NASDAQ:PLRZ)


OwnershipChart

Previous Close

$11.23

52W Range

$2.88 - $18.20

50D Avg

$12.35

200D Avg

$12.58

Market Cap

$12.36M

Avg Vol (3M)

$66.66K

Beta

-1.34

Div Yield

-

PLRZ Company Profile


Polyrizon Ltd. is an Israeli biotechnology firm specializing in the creation of medical device hydrogels, delivered as nasal sprays. These innovative sprays are designed to form a protective barrier within the nasal cavity, preventing viruses and allergens from attaching to the nasal epithelial tissue. Its current development pipeline features several targeted solutions, including PL-14, formulated to block nasal allergies; PL-15, aimed at combating COVID-19; and PL-16, for influenza prevention. Established in 2005, the company operates from its headquarters in Ra'anana, Israel.

Show More

Industry

Biotechnology

Sector

Healthcare

Exchange

NASDAQ

ADR

-

Country

IL

Employees

6

IPO Date

Oct 29, 2024

Website

PLRZ Performance


Peer Comparison


TickerCompany
XTLBXTL Biopharmaceuticals Ltd.
TCRTAlaunos Therapeutics, Inc.
KTTAPasithea Therapeutics Corp.
PMCBPharmaCyte Biotech, Inc.
RADXRadiopharm Theranostics Limited
QNRXQuoin Pharmaceuticals, Ltd.
CYCNCyclerion Therapeutics, Inc.